ArticleCancer medicine2025
Prognosis Prediction and Surgical Benefit Subgroup Analysis in Anal Squamous Cell Carcinoma Patients Undergoing Concurrent Chemoradiotherapy.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anal Squamous Cell Carcinoma with Bilateral Renal Metastases: A Rare Presentation with Literature Review.Current oncology (Toronto, Ont.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to develop a nomogram to predict overall survival in anal squamous cell carcinoma (ASCC) patients undergoing chemoradiotherapy and to identify patients who may benefit from surgery.
methodsData from 4697 ASCC patients were extracted from the Surveillance, Epidemiology, and End Results database. Of these, 2657 patients were included in the training set, 1136 patients in the internal validation set, and 904 patients in the external validation set. LASSO and Cox multivariate regression analyses were conducted to identify independent prognostic factors and construct the nomogram. The discriminatory performance of the nomogram was evaluated using the time-dependent area under the receiver operating characteristic curve (ROC) and calibration curve. Decision curve analysis was used to compare the nomogram with the American Joint Committee on Cancer (AJCC) staging system. Additionally, a risk assessment system based on nomogram scores was developed. Propensity score matching and subgroup analysis were performed to identify groups with potentially better prognosis after surgery.
resultsFour independent variables-age, sex, tumor size, and AJCC stage-were identified as key predictors for the nomogram. The nomogram demonstrated robust discriminatory ability, as evidenced by the time-dependent ROC. Calibration plots showed strong concordance between the nomogram and real-world data in the training and validation cohorts, with the nomogram outperforming the AJCC staging system. Patients were stratified into subgroups based on their risk scores, revealing significant differences in overall survival between the subgroups (p < 0.05). Subgroup analysis suggested that males might benefit from surgery, which was not observed in females.
conclusionThis nomogram could serve as a valuable tool for clinicians in predicting long-term prognosis. We also identified patients who may benefit from surgery, providing a reference for treatment decisions in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.